Zomedica Corp.
Close on Oct 19, 2026
- Market cap
- $77.40M
- P/E (TTM)
- –
- Dividend yield
- –
About Zomedica
Pharmaceutical Preparations, SIC 2834
Zomedica Corp. is an animal health company that develops, manufactures, and markets diagnostic and therapeutic medical devices for companion animals, including dogs, cats, and horses. Its diagnostic offerings include the TRUFORMA point-of-care acoustic wave testing platform, the TRUVIEW automated digital microscopy and cytology system, and the VETGuardian zero-touch vital signs remote monitoring device. Its therapeutic portfolio features PulseVet electrohydraulic shockwave therapy equipment, Assisi targeted pulsed electromagnetic field devices, and VETIGEL hemostatic gel. The company primarily serves clinical veterinarians, veterinary practices, and pet owners.
The company operates manufacturing and distribution facilities in Roswell, Georgia, and a research, development, and manufacturing center in Plymouth, Minnesota. It serves clinical customers in the United States directly through internal sales representatives and domestic distributors. Outside the United States, it commercializes therapeutic products through international distribution networks and a wholly owned subsidiary in Japan. The provided text specifies operational facilities but does not identify the city or address of the corporate headquarters.
Summary of the business section of Zomedica's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Zomedica Corp.
- Founded
- 2013
- Headquarters
- Ann Arbor, MI
- Address
- 1101 Technology Drive, Suite 100 48108
- Phone
- (734) 369-2555
- Employees
- 141, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A0
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Southfield, Michigan
Stock & identifiers
- Ticker
- ZOMDF
- Exchange
- OTC
- IPO date
- Nov 21, 2017
- Shares outstanding
- 980M, Aug 5, 2026
- Public float
- $38.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1684144
- CUSIP
- 98980M109
- ISIN
- US98980M1099
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Larry C. Heaton Ii | CEO, Director | 1,250,000 |
| Anthony K. Blair | COO | 1,000,000 |
| Karen DeHaan-Fullerton | General Counsel | 104,300 |
| Russell Kevin Klass | Sr Vice President, Sales | 6,105,000 |
| Scott Jordan | Chief Financial Officer | 300,000 |
| Johnny D. Powers | Director | 4,425,000 |
| Pamela Nichols | Director | – |
| Sean Whelan | Director | – |
| Rodney James Williams | Director | 301,900 |
| Jeffrey M. Rowe | Director | 13,116,127 |
| Robert Cohen | Director | 543,750 |
| Christopher Ross Macleod | Director | 143,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2023 Larry Heaton | $651.40K | $1.03M | $643.19K | $86960 | – |
| FY2022 Larry Heaton | $1.34M | -$128.92K | $732.81K | $70870 | – |
| FY2021 Larry Heaton | $5.10M | $2.63M | $415.08K | $133480 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 141 employees.”
Corporate history
Events identified from SEC filings